Dangerous Impact of E-Cigarettes on Australian's Health

Regulations by 2FIRSTS.ai
Jan.16.2024
Dangerous Impact of E-Cigarettes on Australian's Health
E-cigarettes have caused serious health complications for 178 Australians, including two deaths and a toddler poisoning.

According to a recent report by Insurance Business Magazine, the latest data from private healthcare institutions in Australia reveals that e-cigarettes have caused serious health complications for 178 individuals in recent years, leading them to require hospitalization. Shockingly, two fatalities have been reported, including one incident of accidental poisoning involving a young child.

 

Data shows that since 2020, a total of seven children under the age of 15 have been hospitalized due to e-cigarette-related illnesses or injuries, including one child who is only two years old. Additionally, nineteen individuals between the ages of 15 and 24 have required hospitalization for e-cigarette use, with an average length of stay of 5.6 days.

 

Dr. Rachel David, CEO of Private Healthcare Australia, suggests that these data may only represent a small portion of actual cases as they only encompass individuals hospitalized under health insurance.

 

She stated, "This further showcases the perilous and addictive threat that e-cigarettes pose to Australians of all age groups, including the potentially oblivious young individuals who may not realize they are gambling with their own health.

 

E-cigarettes, also known as electronic cigarettes, may have a sweet smell and appear mild, but research indicates that they contain up to 200 different chemicals, including herbicides and paint strippers. It is also worth noting that many products claiming to be nicotine-free still contain addictive substances.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
British American Tobacco (BAT) shares rose sharply on May 12 after the U.S. Food and Drug Administration signaled it would deprioritize enforcement against certain unauthorized e-cigarette and nicotine pouch products with accepted premarket applications. Investors viewed the move as favoring established players such as BAT’s Vuse and Velo brands.
BAT
May.13
Multi-State Coalition Urges F1 to End Nicotine Sponsorships, Citing Zyn and Velo
Multi-State Coalition Urges F1 to End Nicotine Sponsorships, Citing Zyn and Velo
Hawaii Attorney General Anne Lopez is co-leading a coalition of 19 states and jurisdictions urging the Fédération Internationale de l’Automobile (FIA) and Formula 1 to end sponsorships involving tobacco and nicotine products, including nicotine pouch brands such as Zyn and Velo.
News
Jun.09
Philip Morris Korea Names Lee Hong-seok as New CEO Effective May 1
Philip Morris Korea Names Lee Hong-seok as New CEO Effective May 1
Philip Morris Korea said on April 29 that it has appointed Lee Hong-seok, head of its smoke-free products division, as its new chief executive officer, with his term beginning on May 1. Yoon Hee-kyung, who took office in 2023, will step down after about three years in the role.
Apr.30 by 2FIRSTS.ai
Canada Recalls Siberia and ZYN Nicotine Pouches Over Unauthorized Sales
Canada Recalls Siberia and ZYN Nicotine Pouches Over Unauthorized Sales
Health Canada has issued a nationwide recall for nicotine pouch products sold under the Siberia and ZYN brands, citing a lack of market authorization. All affected lots are subject to the recall.
Jun.15
From Brands to Supply Chains: 2Firsts Builds a PMTA Compliance Service System for the U.S. Market
From Brands to Supply Chains: 2Firsts Builds a PMTA Compliance Service System for the U.S. Market
2Firsts supports new tobacco and nicotine companies entering the U.S. market with full-chain PMTA compliance services.
Jun.04
 BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
British American Tobacco’s London-listed shares rose 13.99% last week, as investors focused on the U.S. Food and Drug Administration’s recent authorization of flavored Glas e-cigarette products, the dismissal of a U.S. sanctions-related criminal case against BAT, and the company’s previously announced share buyback plan and newer nicotine business performance.
BAT
May.18